NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Thanks for the thoughtful reply. You're right that any company pursuing approval must do some level of preparation, no argument there. The distinction I’m making is about degree, timing, cost, and risk for a company that has been cash-constrained for years.

Yes, you need manufacturing readiness eventually. But actively pursuing U.S. tech transfer (adapting UK SOPs/processes to a U.S. GMP site, personnel training, validation runs, etc.) is one of the more expensive and irreversible steps. It’s not just “planning” — it’s committing real money and management bandwidth at a time when the company has repeatedly said its cash runway is limited.

Look at the key points from the SEC filings:

-They’re not just talking about it. The March 31, 2025 10-Q already showed active discussions with multiple U.S. GMP facilities and stated they expected to reach an agreement that summer. Later filings show this progressed.

-They’re doing the heavy lifting of detailed tech transfer workstreams (new SOPs, cleanroom validation, 3x successful aseptic simulations per operator, full PPQ-style runs, etc.). This is the real, costly work — not just paperwork.

-Flaskworks (their U.S. subsidiary) is being positioned as central to commercial scale, with GMP prototype development, new patents, and integration into the Advent platform specifically including “capacity development in the US” (Oct 24, 2025 PR).

-They’re also building a dedicated leukapheresis clinic, expanding Sawston with Grade C suites enabled by Flaskworks, and integrating everything under one platform.

A rational management team in NWBO’s cash position does not pull the trigger on expensive U.S. tech transfer, facility agreements, and major CapEx commitments, IMHO, unless they have high conviction — based on direct regulatory feedback — that approval is close enough to justify the spend and the risk of burning cash.

Doing the bare minimum to “keep options open” looks very different from what’s actually documented in the SEC filings and PRs, which is why I see the U.S. tech transfer as one of the stronger tells. It’s an “all-in” move for a company that can’t afford any misses.

Curious what you think — do you see these steps as consistent with a company that’s still 2–3+ years away, or more aligned with near-term commercial intent?